Colleen Tupper - Collegium Pharmaceutical Executive CFO
| COLL Stock | USD 33.40 0.27 0.80% |
CFO
Colleen Tupper is Executive CFO of Collegium Pharmaceutical
| Age | 48 |
| Address | 100 Technology Center Drive, Stoughton, MA, United States, 02072 |
| Phone | 781 713 3699 |
| Web | https://www.collegiumpharma.com |
Colleen Tupper Latest Insider Activity
Tracking and analyzing the buying and selling activities of Colleen Tupper against Collegium Pharmaceutical stock is an integral part of due diligence when investing in Collegium Pharmaceutical. Colleen Tupper insider activity provides valuable insight into whether Collegium Pharmaceutical is net buyers or sellers over its current business cycle. Note, Collegium Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Collegium Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Colleen Tupper over a year ago Sale by Colleen Tupper of 31640 shares of Collegium Pharmaceutical |
Collegium Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1056 % which means that it generated a profit of $0.1056 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4643 %, meaning that it created $0.4643 on every $100 dollars invested by stockholders. Collegium Pharmaceutical's management efficiency ratios could be used to measure how well Collegium Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.09 this year. Return On Capital Employed is expected to rise to 0.26 this year. At this time, Collegium Pharmaceutical's Fixed Asset Turnover is quite stable compared to the past year. Return On Assets is expected to rise to 0.04 this year, although the value of Other Assets will most likely fall to about 21.1 M.Similar Executives
| Found 4 records | CFO Age | ||
| Parag Agarwal | Dr Reddys Laboratories | 57 | |
| Christine Sacco | Prestige Brand Holdings | 48 | |
| William MBA | Amphastar P | 56 | |
| Lawrence CPA | Intracellular Th | 68 | |
Management Performance
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.11 |
Collegium Pharmaceutical Leadership Team
Elected by the shareholders, the Collegium Pharmaceutical's board of directors comprises two types of representatives: Collegium Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Collegium. The board's role is to monitor Collegium Pharmaceutical's management team and ensure that shareholders' interests are well served. Collegium Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Collegium Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD FAAFP, Executive Officer | ||
| Bart Dunn, Executive Development | ||
| Scott Dreyer, Executive Vice President Chief Commercial Officer | ||
| Scott Sudduth, Head Operations | ||
| Christopher MD, Vice Relations | ||
| RPh Pharm, CoFounder Chairman | ||
| Marlo Manning, Head HR | ||
| Joseph Ciaffoni, COO, Executive Vice President | ||
| Colleen Tupper, Executive CFO | ||
| Shirley Kuhlmann, Executive Vice President General Counsel, Secretary | ||
| Alex Dasalla, Head Relations | ||
| Richard MD, Ex Officer |
Collegium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Collegium Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 1.42 B | ||||
| Shares Outstanding | 32.72 M | ||||
| Shares Owned By Insiders | 1.41 % | ||||
| Shares Owned By Institutions | 98.59 % | ||||
| Number Of Shares Shorted | 6.86 M | ||||
| Price To Earning | 28.80 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Collegium Pharmaceutical using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Collegium Stock analysis
When running Collegium Pharmaceutical's price analysis, check to measure Collegium Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collegium Pharmaceutical is operating at the current time. Most of Collegium Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Collegium Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collegium Pharmaceutical's price. Additionally, you may evaluate how the addition of Collegium Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Collegium Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 51.976 | Earnings Share 2.51 | Revenue Per Share 17.054 | Quarterly Revenue Growth 0.001 | Return On Assets 0.1056 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.